[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100641759":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":37,"centralContacts":42,"locations":48,"responsibleParty":64,"collaborators":28,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":28,"eligibilityCriteria":72,"healthyVolunteers":68,"sex":73,"minAge":74,"maxAge":28,"enrollmentInfo":75,"targetDuration":28,"studyType":78,"phases":79,"briefSummary":70,"conditions":81,"keywords":28,"overallStatus":83,"whyStopped":28,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Hanmi Pharmaceutical Company Limited","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"HCP1803-4","EXPERIMENTAL","Take HCP1803-3 once daily for 2 weeks orally, and then take HCP1803-4 once daily for 8 weeks orally.",[13,14],"Drug: HCP1803-3","Drug: HCP1803-4",{"label":16,"type":17,"description":18,"interventionNames":19},"RLD2001-2","ACTIVE_COMPARATOR","Take RLD2001-1 once daily for 2 weeks orally, and then take RLD2001-2 once daily for 8 weeks orally.",[20,21],"Drug: RLD2001-1","Drug: RLD2001-2",[23,29,31,35],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","HCP1803-3","Test drug",[9],null,{"type":24,"name":9,"description":26,"armGroupLabels":30,"otherNames":28},[9],{"type":24,"name":32,"description":33,"armGroupLabels":34,"otherNames":28},"RLD2001-1","Control drug",[16],{"type":24,"name":16,"description":33,"armGroupLabels":36,"otherNames":28},[16],[38],{"name":39,"affiliation":40,"role":41},"Moo-Yong Rhee, M.D., Ph.D.","Donggguk University Ilsan Hospital","PRINCIPAL_INVESTIGATOR",[43],{"name":44,"role":45,"phone":46,"phoneExt":28,"email":47},"Jee Won Shon","CONTACT","+82-2-410-9037","jeewon.shon@hanmi.co.kr",[49],{"facility":40,"status":28,"city":50,"state":51,"zip":52,"country":53,"countryCode":28,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"Goyang-si","Gyeonggi-do","10326","South Korea",{"type":55,"coordinates":56},"Point",[57,58],126.835,37.65639,{"lat":58,"lon":57},[61],{"name":39,"role":45,"phone":62,"phoneExt":28,"email":63},"+82-31-961-5775","mooyong.rhee@gmail.com",{"type":65,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR","100641759","phase-3-a-study-to-evaluate-efficacy-and-safety-of-hcp1803-4-in-patients-with-essential-hypertension-100641759",false,"NCT07660796","A Study to Evaluate Efficacy and Safety of HCP1803-4 in Patients With Essential Hypertension","A Multicenter, Randomized, Double-blind, Phase III Study to Evaluate Efficacy and Safety of HCP1803-4 in Patients With Essential Hypertension","Inclusion Criteria:\n\n1. Patients with essential hypertension whose blood pressure measured in visit1 corresponds to the following conditions\n\n   * mean sitSBP \\\u003C 180 mmHg and mean sitDBP \\\u003C 110 mmHg for patients receiving any BP-lowering drug within 1 month prior to Visit 1\n   * 140 mmHg ≤ mean sitSBP \\\u003C 180 mmHg and 60 mmHg ≤ mean sitDBP \\\u003C 110 mmHg for patients not receiving BP-lowering drugs within 1 month prior to Visit 1\n2. Patients with essential hypertension who meet 140 mmHg ≤ mean sitSBP \\\u003C 180 mmHg and 60 mmHg ≤ mean sitDBP \\\u003C 110 mmHg at Visit 2\n\nExclusion Criteria:\n\n1. Difference between arms greater than 20 mmHg for mean sitSBP or 10 mmHg for mean sitDBP at Visit 1\n2. Patients who have taken more than three components of Blood pressure medication within 3 months prior to Visit 1\n3. Orthostatic hypotension with symptoms within 3 months prior to visit 1\n4. Secondary hypertensive patient or suspected to be\n5. Clinically significant hematological finding\n6. Severe heart disease or severe neurovascular disease\n7. Moderate or malignant retinopathy\n8. Uncontrolled diabetes mellitus or type I diabetes mellitus\n9. Active gout or hyperuricemia\n10. Severe renal diseases\n11. Severe or active hepatopathy\n12. Hypokalemia or Hyperkalemia\n13. Hyponatremia or Hypernatremia\n14. Hypercalcemia\n15. History of malignancy tumor\n16. History of autoimmune disease\n17. History of alcohol or drug abuse\n18. Positive to pregnancy test, nursing mother, intention on pregnancy\n19. Considered by investigator as not appropriate to participate in the clinical study with other reason","ALL","19 Years",{"count":76,"type":77},256,"ESTIMATED","INTERVENTIONAL",[80],"PHASE3",[82],"Hypertension","NOT_YET_RECRUITING","2026-06-26",{"date":86,"type":87},"2026-06-30","ACTUAL",{"date":89,"type":77},"2026-07-06",{"date":91,"type":77},"2027-11-30",{"name":5,"class":6},1]